ES2148365T3 - Preparacion farmaceutica controlada para liberar ingrediente activo medicinal en un lugar diana en el tracto intestinal. - Google Patents

Preparacion farmaceutica controlada para liberar ingrediente activo medicinal en un lugar diana en el tracto intestinal.

Info

Publication number
ES2148365T3
ES2148365T3 ES95103493T ES95103493T ES2148365T3 ES 2148365 T3 ES2148365 T3 ES 2148365T3 ES 95103493 T ES95103493 T ES 95103493T ES 95103493 T ES95103493 T ES 95103493T ES 2148365 T3 ES2148365 T3 ES 2148365T3
Authority
ES
Spain
Prior art keywords
pharmaceutical preparation
intestinal tract
medicinal ingredient
active medicinal
release active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95103493T
Other languages
English (en)
Inventor
Yoshiyuki Hirakawa
Hiroyuki Yoshino
Eiji Fukui
Tami Hanamori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12593695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2148365(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Application granted granted Critical
Publication of ES2148365T3 publication Critical patent/ES2148365T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PRESENTA UNA PREPARACION FARMACEUTICA DE ADMINISTRACION ORAL QUE ES CONTROLADA PARA LIBERAR UN INGREDIENTE MEDICINAL ACTIVO EN UN LUGAR SELECCIONADO DEL TRACTO INTESTINAL QUE COMPRENDE (A) UN NUCLEO CON UN INGREDIENTE ACTIVO MEDICINAL Y (B) UNA ENVOLTURA SATINADA QUE CONSTA DE UN POLIMERO ENTERICO, QUE CUBRE EL NUCLEO. EN LA PREPARACION FARMACEUTICA DEL PRESENTE INVENTO EL INGREDIENTE MEDICINAL ACTIVO NO ES LIBERADO DURANTE SU ESTANCIA EN EL ESTOMAGO SINO, TRAS SER ARROJADA DEL ESTOMAGO, HASTA ALCANZAR UN LUGAR ELEGIDO DEL INTESTINO, TRAS LO CUAL ES LIBERADO RAPIDAMENTE SIENDO REPARTIDO EN EL LUGAR DESEADO DEL TRACTO INTESTINAL.
ES95103493T 1994-03-11 1995-03-10 Preparacion farmaceutica controlada para liberar ingrediente activo medicinal en un lugar diana en el tracto intestinal. Expired - Lifetime ES2148365T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6040911A JP2917799B2 (ja) 1994-03-11 1994-03-11 消化管内適所放出型製剤

Publications (1)

Publication Number Publication Date
ES2148365T3 true ES2148365T3 (es) 2000-10-16

Family

ID=12593695

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95103493T Expired - Lifetime ES2148365T3 (es) 1994-03-11 1995-03-10 Preparacion farmaceutica controlada para liberar ingrediente activo medicinal en un lugar diana en el tracto intestinal.

Country Status (14)

Country Link
US (1) US5725880A (es)
EP (1) EP0671168B1 (es)
JP (1) JP2917799B2 (es)
KR (1) KR100305234B1 (es)
CN (1) CN1116523A (es)
AT (1) ATE193439T1 (es)
CA (1) CA2144094C (es)
DE (1) DE69517218T2 (es)
DK (1) DK0671168T3 (es)
ES (1) ES2148365T3 (es)
GR (1) GR3033593T3 (es)
PT (1) PT671168E (es)
SG (1) SG34210A1 (es)
TW (1) TW422708B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2120354B1 (es) * 1996-02-12 1999-07-01 Univ Sevilla Dispositivo terapeutico para direccionar farmacos hacia el tramo del tracto gastrointestinal deseado en funcion de las caracteristicas fisicoquimicas del mismo.
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
DE69924735T2 (de) * 1998-07-28 2006-01-19 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
DE59905248D1 (de) 1999-01-29 2003-05-28 Disphar Int Bv Pharmazeutische zusammensetzungen
FR2790387B1 (fr) * 1999-03-01 2001-05-18 Prographarm Laboratoires Comprime orodispersible presentant une faible friabilite et son procede de preparation
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
KR100574213B1 (ko) 2000-01-27 2006-04-27 다나베 세이야꾸 가부시키가이샤 서방성 제제 및 그의 제조 방법
US6420473B1 (en) 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
CN1216596C (zh) * 2000-02-10 2005-08-31 Bpsi控股公司 丙烯酸肠溶性涂层组合物
IT1318625B1 (it) * 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
EP1607087A1 (en) * 2003-03-27 2005-12-21 Hisamitsu Pharmaceutical Co., Inc. Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
GB0320522D0 (en) * 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
US20060062811A1 (en) * 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
WO2007010846A1 (ja) * 2005-07-15 2007-01-25 Kissei Pharmaceutical Co., Ltd. 胃内滞留製剤
HUE031042T2 (en) 2005-07-29 2017-06-28 Abbott Laboratories Gmbh Methods for producing pancreatin powder with low viral content
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
DK1931316T4 (en) 2005-08-15 2017-05-15 Abbott Laboratories Gmbh Controlled-release pharmaceutical compositions for use in acid-labile drugs
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
CA2673485A1 (en) * 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
US20100303901A1 (en) * 2007-04-26 2010-12-02 Eyal Shimoni Oral delivery of proteins and peptides
NZ581710A (en) * 2007-06-13 2012-02-24 Jay Pravda Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
JP5740306B2 (ja) 2008-10-03 2015-06-24 ドクトル ファルク ファルマ ゲーエムベーハー メサラミン顆粒を用いて腸疾患を治療するための組成物および方法
EP2255794A1 (en) * 2009-05-29 2010-12-01 H e x a l Aktiengesellschaft Enteric coating
JP5496616B2 (ja) * 2009-11-18 2014-05-21 フロイント産業株式会社 大腸ドラッグデリバリーシステム製剤
EP3439676B1 (en) 2016-04-04 2021-06-09 Omeza LLC Fish oil topical composition
US10765635B2 (en) * 2018-02-06 2020-09-08 Nano Pharmaceutical Laboratories Llc Multiparticulate including pharmaceutical or probiotic active ingredients for delivery via a shelf stable liquid dosage form
US20240189236A1 (en) * 2021-07-09 2024-06-13 Evonik Operations Gmbh Composition comprising a (meth)acrylate copolymer, an alkali or ammonium salt of a saturated aliphatic monocarboxylic acid and specific glidants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3325365A (en) * 1963-04-02 1967-06-13 Ciba Geigy Corp Enteric composition for tablet compression coating
US3608030A (en) * 1969-05-21 1971-09-21 Howard Tint Method of preparing a tablet dosage-form for the immunization of the intestinal tract with live virus preparations
GB1456365A (en) * 1972-10-06 1976-11-24 Gist Brocades Nv Controlled release composition
CA1308357C (en) * 1987-01-28 1992-10-06 Tohru Chiba Method for the preparation of a coated solid medicament
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition

Also Published As

Publication number Publication date
DE69517218D1 (de) 2000-07-06
CA2144094A1 (en) 1995-09-12
ATE193439T1 (de) 2000-06-15
TW422708B (en) 2001-02-21
DE69517218T2 (de) 2000-11-30
JPH07247222A (ja) 1995-09-26
EP0671168B1 (en) 2000-05-31
CA2144094C (en) 2004-01-27
EP0671168A1 (en) 1995-09-13
CN1116523A (zh) 1996-02-14
KR100305234B1 (ko) 2002-04-24
US5725880A (en) 1998-03-10
KR950031046A (ko) 1995-12-18
DK0671168T3 (da) 2000-08-07
JP2917799B2 (ja) 1999-07-12
GR3033593T3 (en) 2000-09-29
PT671168E (pt) 2000-09-29
SG34210A1 (en) 1996-12-06

Similar Documents

Publication Publication Date Title
ES2148365T3 (es) Preparacion farmaceutica controlada para liberar ingrediente activo medicinal en un lugar diana en el tracto intestinal.
ATE129404T1 (de) Dosierungsform fuer die freisetzung eines witkstoffs in einem kurzen zeitraum.
CO4750822A1 (es) Formulaciones farmaceuticas tada para la administracion en el tracto gastrointestinal y procesos para elaborar las mismas
ATE201991T1 (de) Bisacodyl dosierungsform
EA200301321A1 (ru) Фармацевтические композиции для координированной доставки средств нестероидных противовоспалительных лекарственных средств
ATE102029T1 (de) Dosierungsform zur verabreichung eines arzneimittels an die daerme.
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
MX9500885A (es) Preparacion farmaceutica para administracion oral.
ATE277594T1 (de) Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
AR062167A1 (es) Sistema de administracion gastrorretentivo
PT989848E (pt) Comprimido com revestimento em filme para uma melhor seguranca de tracto gastrointestinal superior
AR019031A1 (es) Forma farmaceutica de dosificacion de efavirenz en capsula o tableta comprimida y metodo para su preparacion
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
KR900015724A (ko) 메베버린 용량 형태
AR022338A1 (es) Un compuesto de benzamida, medicamento que lo contiene, y uso para la manufactura de un medicamento para el tratamiento o prevencion de una enfermedad digestiva o para mejorar la movilidad del tracto gastrointestinal.
ATE165239T1 (de) Orale arzeimittelzubereitung enthaltend diclofenac-natrium und eine organische säure
RU2002121267A (ru) Способ профилактики и лечения язв желудка у животных
RU2007129408A (ru) Способ выращивания поросят в период откорма
SE9601080L (sv) Kapsel för införande av läkemedel i magen på boskap
Tabata et al. Irritative activity of a new anti-inflammatory agent 4-(p-chorophenyl)-2-phenyl-5-thiazoleacetic acid (CH-800) on the gastrointestinal tract in rats (author's transl)
TH65058A3 (th) วิธีการและสารผสมสำหรับการบำบัดอาการอักเสบ
SE8502039D0 (sv) New drug compositions of antimicrobial activity and process for their preparation
SE9003096D0 (sv) Device for administering a physiologically active substance to the gastro-intestinal tract
IT1254688B (it) Composizioni farmaceutiche somministrabili per via orale a rilascio mirato contenenti acido ursodesossicolico ed acido chenodesossicolico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 671168

Country of ref document: ES